The world is a daily classroom on basic economics principles: from the Greece bailout, to the austerity measures in several EU countries, to debate over the Chinese yuan currency, to the American recession and Occupy Wall Street protests.
DetailsThere is a tug-of-war going on between the European Commission, with laws intended to protect the free market, and business sectors hoping to claim (or retain) exclusivity. National EU governments are using those laws to their advantage to obtain prescription drugs for the lowest prices.
DetailsThe healthcare reform bill was only passed at the end of March but its effects are already being reported by some of the biggest players in the pharmaceutical industry
DetailsComparative effectiveness has really come to the fore following the Healthcare Reform Bill and has the potential to seriously affect businesses in the healthcare industry. But is it all just a misunderstood can of worms?
DetailsThe future of medical publishing might be e-publishing. Will there be a role for print journals?
DetailsFrom e-books on Amazon.com to a new publishing format by the BMJ, e-reading is here to stay, and things will never be the same in medical publications.
DetailsYou can prove just about anything with statistics. We’ve seen this in polls, politics, and policy. Even in health economics, caveat emptor.
DetailsWe’ve all seen our share of silly headlines or sound bites, but they become a more serious matter when health or money is at stake.
DetailsThe UK National Institute for Health and Clinical Excellence (NICE) has overhauled its technology appeals process with the aim of making it quicker and slicker. Despite the efforts at greater clarity, the short period for appealing final decisions remains, so time is of the essence.
DetailsUpdated guidance on the appeals process for technology appraisals doesn’t exactly conjure up sexy headlines, but the process affects everyone – manufacturer, provider, and patient – so it’s worth the read.
Details
